ChainCatcher 消息，据市场消息，数字资产财务公司 Propanc Biopharma（纳斯达克股票代码：PPCB）周一表示，已从活跃于比特币、以太坊、Solana、狗狗币及其他数字资产领域的家族办公室 Hexstone Capital 获得高达 1 亿美元融资。
此次私募交易通过可转换优先股结构进行，Propanc 将获得 100 万美元初始投资，并在未来一年内获得高达 9900 万美元的后续资金。所得款项将用于构建 Propanc 的数字资产投资组合，并加速其主打肿瘤疗法 PRP 的研发进程，该疗法目前计划于 2026 年开展首次人体试验。首席执行官 James Nathanielsz 称此举为“转型阶段”，旨在强化公司资产负债表并为其基于前酶的研究项目提供资金支持。公司未具体说明计划收购哪些数字资产。融资消息并未止住 Propanc 股价的跌势。周一，PPCB 股价下跌 4%，跌破 1 美元，过去一个月累计跌幅已达 43%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.